Join us for an audio catch-up on the major events in the global biopharma industry over the past business week, as reported by Scrip‘s global team, in this podcast version of Five Must-Know Things.
This episode covers insights for the business week ended 18 October 2024, including: J&J looks to Tremfya as Stelara declines; Pfizer’s Hympavzi may find hemophilia B niche; big pharma’s cell and gene therapy realities; M&A took a holiday in Q3; and last rites for Sanofi’s RIPK1 drug.
This and all our other podcasts are available on the Citeline channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.
Stories mentioned in this episode:
As Stelara Sunset Begins, J&J Says Tremfya Will Step Up
Pfizer’s Hympavzi May Fall Into Hemophilia B Niche
Big Pharma Faces Cell And Gene Therapy Market Realities
M&A Took A Holiday In Q3, With Decreased Volume And Value
Sanofi RIPK1 Drug Receives Last Rites